Laurus Labs Acquires Majority Stake in Galenvs Sciences
The Indian pharmaceutical firm plans to invest $3.75 million into the Canadian biotechnology company.
Updated on Oct. 29, 2026 in Healthcare
Live Poll
Do you believe large pharmaceutical companies acquiring smaller biotech startups benefits the healthcare market?
Laurus Labs has signed a definitive agreement to acquire a 60% stake in Galenvs Sciences. The total investment includes a primary infusion of $2.75 million for the Canadian company.
Why it matters
The investment aims to bolster capabilities in oligonucleotide development and manufacturing. It also seeks to expand the company's offerings within the contract development and manufacturing organization market.
Laurus Labs is investing a total of $3.75 million into Galenvs Sciences, which carries a pre-money valuation of $3.5 million. The deal secures a 60% stake for the buyer, including an immediate primary cash infusion of $2.75 million.
The players
Laurus Labs
Headquartered in Hyderabad, this pharmaceutical company specializes in active pharmaceutical ingredients, synthesis, and biotechnology.
Galenvs Sciences
This Canadian biotechnology firm focuses on the development of magnetic nanoparticles and advanced DNA and RNA technologies.
The details
The companies intend to use the funds to expand scientific talent in Montréal and increase manufacturing infrastructure in India. The completion of this acquisition remains subject to the final results of due diligence.
Timeline
October 29, 2026: Laurus Labs announced the acquisition agreement to the bourses.
Market Landscape
This move highlights the ongoing expansion of global CDMO services as companies race to secure niche technological capabilities. It positions Laurus Labs to compete more effectively by integrating specialized DNA and RNA research directly into its manufacturing pipeline.
Customers of the combined firm may see expanded availability of complex oligonucleotide services as the company scales its infrastructure. The deal is unlikely to result in immediate changes to retail pricing or consumer-facing product availability.
The takeaway
Strategic investments in niche biotechnology are becoming a primary method for larger firms to accelerate their R&D timelines. Investors and industry observers should watch for updates once the due diligence process concludes.
Further reading
For more on industry shifts, visit the Healthcare section.
Source note: This article includes information reported by The Times of India.
Live Poll
Do you believe large pharmaceutical companies acquiring smaller biotech startups benefits the healthcare market?
